BCR-ABL Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033

BCR-ABL Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative and qualitative market trends within In Vitro Diagnostics therapeutic area.

Leukemia is a heterogeneous group of cancers that affects the blood and bone marrow. Two common subtypes are lymphocytic leukemia's and myeloid leukemia's, which derive from lymphoid cells and myeloid cells, respectively. Breakpoint Cluster Region- Tyrosine-Protein Kinase ABL1 fusion gene (BCR-ABL) tests are carried out to detect fusion gene mutations in patient tissue samples; the outcome of which may guide therapies to treat various cancers including chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML).

BCR-ABL is a mutation, also known as the Philadelphia (Ph) chromosome, which is formed by a reciprocal chromosomal translocation of the BCR gene on chromosome 22 with the ABL1 gene on chromosome 9.

Each of the covered 39 countries color-coded and fully-sourced market models are equipped with epidemiology based indications. The interactive excel deliverable covers value, volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are -

Currently marketed BCR-ABL tests and evolving competitive landscape -

• Insightful review of the key industry trends.
• Annualized total BCR-ABL tests market revenue by segment and market outlooks from 2015-2033.
• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights -

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for BCR-ABL Tests market.
• Competitive dynamics insights and trends provided for BCR-ABL Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Abbott Laboratories, Oxford Gene Technology Inc, Asuragen Inc, Cepheid Inc, Bio-Rad Laboratories Inc, Qiagen NV, Agilent Technologies Inc, Illumina Inc, Thermo Fisher Scientific Inc, Takara Bio Inc

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the BCR-ABL Tests market place to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products, by identifying key companies.
• Develop business strategies by understanding the trends shaping and driving BCR-ABL Tests market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the BCR-ABL Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track device sales in the global and country-specific BCR-ABL Tests market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.